Several anti-PD1 or anti-PD-L1 antibodies have been approved, for treatment of various types of cancer, including such as durvalumab (anti-PD-L1), nivolumab (anti-PD1) and pembrolizumab (anti-PD1), which are used to treat skin cancer, NSCLC, SCLC, HCC, bile duct cancer, endometrial cancer and certain types of breast cancer. This evidence concerns the gene CD274 and breast cancer.